Stock Pick

  • 2 ASX shares in the fight against coronavirus

    coronavirus positioned on stock market graph, asx shares

    The potential for a vaccine for coronavirus has flooded news headlines recently, causing some ASX shares to rally. The rush to find a ‘silver bullet’ cure for the pandemic has resulted in a slew of listed companies announcing their intentions to undertake research around a possible cure. 

    Despite the optimism and enthusiasm for a vaccine, many scientists have indicated that a well-trialled and tested vaccine for COVID-19 could take much longer than 18 months to develop. The vast majority of vaccines fail somewhere between Phase 1 and Phase 2 trials.

    Given the nature of COVID-19 and the trial processes involved in vaccine development, companies that have joined the race to find a cure could face a long and costly journey. As a result, the focus has also turned to alternative methods of treating and testing for COVID-19.

    Here are 2 ASX biotechnology companies that have joined the fight against COVID-19.   

    2 ASX shares involved the fight against coronavirus

    Mesoblast limited (ASX: MSB)

    Mesoblast is a world leader in developing regenerative medicines for inflammatory diseases and prides itself on innovation surrounding stem cell research. The company made headlines late last month after announcing promising results for its remestemcel-L treatment for COVID-19. In a US trial, Mesoblast recorded an 83% survival rate in ventilator-dependent COVID-19 patients, while 75% of patients had successfully come off ventilator support within 10 days.

    Mesoblast’s remestemcel-L product acts by counteracting the inflammatory processes caused by COVID-19. The company is currently undertaking a $46 million Phase 2/3 trial in the US in order to attain approval from the US Food and Drug Administration.

    The promising results from its US trials has seen the Mesoblast share price surge more than 250% from its lows in mid-March.  The company recently completed a $138 million capital raising in order to scale-up manufacturing of its products and is also in the process of conducting clinical trials in Australia.

    CSL Limited (ASX: CSL)

    CSL is not actively participating in the race to develop a vaccine for COVID-19. The biotechnology giant is, however, working hard to develop a plasma product that may assist in the recovery of patients battling the disease. In collaboration with the Australian Red Cross Lifeblood Service, CSL is collecting plasma from patients who have recovered from COVID-19. The collected plasma, which contains antibodies, will then be used to support a clinical trial aimed at improving the condition of COVID-19 patients and reducing their need for ventilation.  

    Should you buy these ASX shares?

    Despite the optimism surrounding a coronavirus vaccine, the reality is that a successful solution will not happen overnight. Biotech companies have to undergo arduous and costly approval processes and clinical trails before actually getting a product to market.

    As a result, I think investors should exercise caution when companies announce their intentions to fight COVID-19. In my opinion, if you’re keen on investing in the sector, tried and tested performers like CSL would be the best, long-term option as they offer greater risk protection.

    If you’re not liking the look of these 2 ASX biotech shares, check out this report for more blue-chip performers like CSL.

    The Motley Fool AU Announces Top 3 Dividend Shares To Buy For 2020

    When Edward Vesely — The Motley Fool Australia’s resident dividend expert — has a stock tip, it can pay to listen. With huge winners like Dicker Data (up 92%) and SDI Limited (up 53%) under his belt, Edward is building an enviable following amongst investors that are planning for retirement.

    In a brand new report, Edward has just revealed what he believes are the 3 best dividend stocks for income-hungry investors to buy now. All 3 stocks are paying growing fully franked dividends giving you the opportunity to combine capital appreciation with attractive dividend yields.

    Best of all, Edward’s “Top 3 Dividend Shares To Buy For 2020” report is totally free to all Motley Fool readers.

    As of 7/4/2020

    Click here now to access this free report.

    More reading

    Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 2 ASX shares in the fight against coronavirus appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2A2bfDZ

  • U.S.-Chine Ties Have Become ‘Extremely Hostile,’ Former Official Says

    U.S.-Chine Ties Have Become 'Extremely Hostile,' Former Official SaysMay.24 — Susan Shirk, a former deputy assistant secretary of state during the Clinton administration and currently a professor chair of the 21st Century China Center at the School of Global Policy and Strategy at the University of California, San Diego, looks at the tensions between the U.S. and China. The U.S. should give up its “wishful thinking” of changing China, Foreign Minister Wang Yi said, warning that some in America were pushing relations to a “new Cold War.” Shirk speaks on “Bloomberg Markets: Asia.”

    from Yahoo Finance https://ift.tt/3e81faW

  • 3 top ASX growth shares to buy with $3,000

    asx growth shares

    If you’re looking to make a long term investment in a collection of ASX growth shares, then the three listed below could be worth considering.

    I believe all three have the potential to deliver returns that smash the market over the next decade. Here’s why I would invest $3,000 into them:

    BetaShares Asia Technology Tigers ETF (ASX: ASIA)

    The first option for growth investors to consider buying is the BetaShares Asia Technology Tigers ETF. This exchange traded fund provides investors with exposure to a number of exciting tech shares in the Asian market. These include the likes of ecommerce giants Alibaba and JD.com, search engine company Baidu, and new Afterpay Ltd (ASX: APT) shareholder and WeChat owner, Tencent. Given how these companies are revolutionising the lives of billions of people in the region, I believe they are well-positioned for strong growth over the next decade.

    Cochlear Limited (ASX: COH)

    Another ASX growth share to consider buying is Cochlear. I like this hearing solutions company due to its exposure to the ageing populations tailwind. As people age, their hearing will often fade and require some form of assistance. I expect this to lead to increasing demand for hearing solutions products over the next couple of decades. Given Cochlear has industry-leading products and a wide distribution network, I expect it to benefit greatly from this.

    Domino’s Pizza Enterprises Ltd (ASX: DMP)

    Another top ASX growth share to buy could be Domino’s Pizza. I believe the pizza chain operator is well positioned to deliver more than just pizzas over the next decade. I expect a helping of strong returns as well. Especially given its same store sales and store expansion goals. Over the next five years the company is aiming to deliver annual same store sales growth of 3% to 6% and annual organic new store additions of 7% to 9%. If it can maintain its margins, this should support strong earnings growth over the next decade.

    And here is a fourth option for growth investors that you might regret missing out on…

    One “All In” ASX Buy Alert, that could be one of our greatest discoveries

    Investing expert Scott Phillips has just named what he believes is the #1 Top “Buy Alert” after stumbling upon a little-owned opportunity he believes could be one of the greatest discoveries of his 25 years as a professional investor.

    This under-the-radar ASX recommendation is virtually unknown among individual investors, and no wonder.

    What it offers is an utterly unique strategy to position yourself to potentially profit alongside some of the world’s biggest and most powerful tech companies.

    Potential returns of 1X, 2X and even 3X are all in play. Best of all, you could hold onto this little-known equity for DECADES to come.

    Simply click here to see how you can find out the name of this ‘all in’ buy alert… before the next stock market rally.

    Find out the name of Scott’s ‘All in’ Buy Alert

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia owns shares of and has recommended BetaShares Asia Technology Tigers ETF. The Motley Fool Australia has recommended Cochlear Ltd. and Domino’s Pizza Enterprises Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post 3 top ASX growth shares to buy with $3,000 appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3gq9ilx

The Latest

Sorry, but nothing was found. Please try a search with different keywords.